Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Cara has a non-exclusive, royalty-bearing license to the Peptelligence technology to develop, manufacture and commercialize Oral KORSUVA
August 26, 2019
By: Kristin Brooks
Enteris BioPharma, Inc., a biotechnology company, has entered a definitive licensing agreement with Cara Therapeutics for Enteris’ Peptelligencetechnology in the ongoing development of an oral formulation of Cara’s first-in-class KOR agonist, CR845/difelikefalin, KORSUVA. Peptelligence is Enteris’ platform for the oral delivery of peptides and BCS class II, III and IV small molecules. The oral tablet formulation of KORSUVA (Oral KORSUVA) was engineered using Peptelligence, and is currently in three separate Phase II trials for pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC), stage III-V chronic kidney disease (CKD), and atopic dermatitis (AD). This agreement will allow Cara to continue its Oral KORSUVA programs into Phase III and beyond. Under the terms, Cara Therapeutics has a non-exclusive, royalty-bearing license to the Peptelligence technology to develop, manufacture and commercialize Oral KORSUVA worldwide, excluding Japan and South Korea. In exchange, Enteris will receive an upfront payment of $8 million, with 50% payable in cash and 50% payable in shares of Cara’s common stock. Cara will also pay Enteris milestone payments upon the achievement of certain development, regulatory and commercial milestones and royalties based on sales in the licensed territory. Cara retains the right to buy-out the royalty obligation for a period of two years under prespecified conditions. “This is a watershed moment for Enteris and our Peptelligence® platform, and we greatly welcome the opportunity to deepen our relationship with Cara Therapeutics in the ongoing development of its Oral Korsuva™ pipeline,” said Joel Tune, CEO of Enteris BioPharma. “The ability of our Peptelligence® platform to enable the oral delivery of peptide therapeutics, such as CR845/difelikefalin, is a potential game-changer for numerous peptide and small molecule-based drugs in development and on the market given the convenience and marketability of an orally administered tablet in comparison to an injection.” “We are pleased to formalize our ongoing work with Enteris and look forward to the continued advance of our Oral KORSUVA™ program, which now includes three Phase 2 clinical trials in pruritus settings,” stated Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “Effective treatment of pruritus remains a significant unmet need in patients with atopic dermatitis, liver disease and chronic kidney disease, adding to their discomfort and seriously impacting patients’ quality of life, including sleep disruption, altered eating habits, anxiety and depression. We believe that KORSUVA may provide a potential, first-in-class therapeutic to treat pruritus across clinical populations, and the ability to deliver it via an oral tablet formulation expands patient accessibility to the benefits of the product, if approved.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !